Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study

被引：0
|
作者：
Daniel Reinhorn
Iryna Kuchuk
Tzippy Shochat
Bella Nisenbaum
Aaron Sulkes
Daniel Hendler
Ofer Rotem
Daliah Tsoref
Olga Olitzky
Hadar Goldvaser
Michal Sarfaty
Victoria Neiman
Judit Prus
Maya Gottfried
Shlomit Yust-Katz
Rinat Yerushalmi
机构：
[1] Beilinson Hospital,Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center
[2] Meir Medical Center,Department of Oncology
[3] Tel Aviv University,Sackler Faculty of Medicine
[4] Beilinson Hospital,Statistical Consulting Unit
[5] Rabin Medical Center,undefined
来源：
Breast Cancer Research and Treatment | 2021年 / 188卷
关键词：
Breast cancer; Metastatic; HER-2 positive; Vinorelbine; Taxane; Trastuzumab; Pertuzumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：379 / 387
页数：8
相关论文
共 50 条
  • [1] Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study
    Reinhorn, Daniel
    Kuchuk, Iryna
    Shochat, Tzippy
    Nisenbaum, Bella
    Sulkes, Aaron
    Hendler, Daniel
    Rotem, Ofer
    Tsoref, Daliah
    Olitzky, Olga
    Goldvaser, Hadar
    Sarfaty, Michal
    Neiman, Victoria
    Prus, Judit
    Gottfried, Maya
    Yust-Katz, Shlomit
    Yerushalmi, Rinat
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2021, 188 (02) : 379 - 387
  • [2] Taxane versus vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with metastatic HER2-positive breast cancer - A retrospective two-center study
    Reinhorn, Daniel Jack
    Kuchuk, Irina
    Prus, Judit
    Sarfaty, Michal
    Goldvaser, Hadar
    Rotem, Ofer
    Hendler, Daniel
    Zoref, Dalia
    Neiman, Victoria
    Shohat, Tzipora
    Ulitsky, Olga
    Yust-Katz, Shlomit
    Nisenbaum, Bella
    Gottfried, Maya
    Yerushalmi, Rinat
    [J]. CANCER RESEARCH, 2020, 80 (04)
  • [3] Interim safety of pertuzumab in combination with trastuzumab and vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E.
    Lopez-Vega, J. M.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : S178 - S179
  • [4] Pertuzumab In the First-Line Treatment of HER2-Positive Metastatic Breast Cancer
    Keating, Gillian M.
    [J]. DRUGS, 2012, 72 (03) : 353 - 360
  • [5] Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E. A.
    Lopez-Vega, J. M.
    Del Mastro, L.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    [J]. CANCER RESEARCH, 2013, 73
  • [6] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Farhat, Fadi
    Kattan, Joseph G.
    Ghosn, Marwan
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1069 - 1077
  • [7] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Fadi Farhat
    Joseph G. Kattan
    Marwan Ghosn
    [J]. Cancer Chemotherapy and Pharmacology, 2016, 77 : 1069 - 1077
  • [8] Phase II Study of a Triple Combination of Oral Vinorelbine, Capecitabine and Trastuzumab as First-line Treatment in HER2-positive Metastatic Breast Cancer
    Chan, Arlene
    Conte, Pier-Franco
    Petruzelka, Lubos
    Tubiana-Mathieu, Nicole
    Ganju, Vinod
    Llombart, Antonio
    Espie, Marc
    Majois, Francoise
    Gil, Miguel Gil
    Vaissiere, Nathalie
    Villanova, Gustavo
    [J]. ANTICANCER RESEARCH, 2013, 33 (06) : 2657 - 2664
  • [9] A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET).
    Perez, Edith A.
    Manuel Lopez-Vega, Jose
    Del Mastro, Lucia
    Petit, Thierry
    Mitchell, Lada
    Pelizon, Christina H.
    Andersson, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND A TAXANE FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HER2-POSITIVE ADVANCED BREAST CANCER: A SINGLE ARM PHASE IIIB STUDY (PERUSE)
    Miles, D.
    Peretz-Yablonski, T.
    Ciruelos, E.
    Puglisi, F.
    Schneeweiss, A.
    Mitchell, L.
    Duenne, A.
    Bachelot, T.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 142 - 143
12345